- Kura Oncology (NASDAQ:KURA) -29% after FDA places KO-539 study on partial hold.
- Vallon Pharmaceuticals (NASDAQ:VLON) -29%.
- Aptevo Therapeutics (NASDAQ:APVO) -27%.
- Nordstrom (NYSE:JWN) -26% on Q3 earnings release.
- Petros Pharmaceuticals (NASDAQ:PTPI) -22%.
- Outlook Therapeutics (NASDAQ:OTLK) -22% after secures $50M capital through stock offering.
- Qualigen Therapeutics (NASDAQ:QLGN) -21%.
- Anaplan (NYSE:PLAN) -20% on Q3 earnings release.
- The Gap (NYSE:GPS) -20% on Q3 earnings release.
- iSpecimen (NASDAQ:ISPC) -18%.
- Viomi Technology (NASDAQ:VIOT) -17% on Q3 earnings release.
- Autodesk (NASDAQ:ADSK) -13% on Q3 earnings release.
- Clarus Therapeutics Holdings (NASDAQ:CRXT) -13%.
- Esperion Therapeutics (NASDAQ:ESPR) -13%.
- MediciNova (NASDAQ:MNOV) -12%.
- PainReform (NASDAQ:PRFX) -9%.
- Unity Biotechnology (NASDAQ:UBX) -9%.
- Faraday Future Intelligent Electric (NASDAQ:FFIE) -7% as company delays 10-Q filing
- Greenland Technologies (NASDAQ:GTEC) -6%.
- Gracell Biotechnologies (NASDAQ:GRCL) -6%.
- ContextLogic (NASDAQ:WISH) -5%.
- Progenity (NASDAQ:PROG) -5%.